Police reveal why they raided Plymouth ‘cannabis shop’ as two people arrested

Source: https://www.plymouthherald.co.uk/news/plymouth-news/police-reveal-raided-plymouth-cannabis-2690838


Police have said they were “legally obliged” to carry out their operation this morning after evidence revealed items being sold in a city store were deemed illegal by law.

Two people – a 35-year-old man and a 25-year-old woman – have been arrested on suspicion of being concerned in the supply of class B drugs after police executed two search warrants this morning. The man has also been arrested on suspicion of money laundering.

Shortly after 7.30am officers from Plymouth police’s south and central CID and neighbourhood teams attended a flat in a residential property in Houndiscombe Road, Mutley, where they carried out a search.

Keys were acquired and officers carried out a further search of the Holy Smoke hut-like store which sits near the Voodoo Lounge club and the Jigsaw Garden.

Police have told Plymouth Live a four-figure sum of cash was seized from the residential property along with cultivation equipment including grow lamps, tents, trays and fertilizer.

Police revealed that a “substantial quantity of suspected cannabis” and other drug-related paraphernalia was also found at the property. A number of bottles of “e-liquid” purporting to contain “90 percent THC” have also been seized.

Detectives also seized a number of mobile phones, a laptop, a SUV Dodge Nitro vehicle and a quantity of documentation including invoices.

Scene of Crime Officers have also been at the property to carry out forensic examinations.

Officers also seized CCTV recording equipment from the Holy Smoke store, which is rented from the nearby Methodist Central Hall.

This morning’s operation was described as pre-planned and police have revealed it came about following analysis of herbal material recovered from juveniles arrest following a theft from the Holy Smoke store.

Insp Robin Loveridge, neighbourhood inspector for the city centre, told Plymouth Live the theft of bell jars containing herbal matter from the store was reported to police. Two juveniles were traced and the jar and its contents were recovered, but police took the step of having the material tested in a laboratory.

Insp Loveridge said: “It came back as positive for THC – we don’t look at percentages with regard to cannabis. In effect, it is a class B drug and our view was we have to investigate this as the suspected selling of a class B drug.

“We went to our force legal department for advice and looked at the Home Office guidelines on the matter.

“Officer from the neighbourhood team went to the store and spoke to the proprietor. He has produced a certificate which we passed to our force legal department.

“Home Office guidelines show that you have to have certain licences to grow cannabis. There are no licences to sell cannabis to the public.

“Our CID team has carried out the investigation and executed the search warrants and the neighbourhood policing teams will pick up the community fall-out from today’s operation.”

Insp Loveridge stressed the reason there appeared to be a large number of officers involved in what was considered a small and simple operation was because a number of the officers involved were undergoing training alongside tutor officers. He said the operation gave them opportunity to learn the process of a section 8 PACE [Police and Criminal Evidence Act] search warrant.

He added: “This was a pre-planned operation and had been in the planning stage for some time, certainly well before the article [about the Holy Smoke store] appeared on the Plymouth Live website.

“The article did not change our time frame for out action.

“We would like to point out at this stage that once evidence is gathered it will be passed to the Crown Prosecution Service for their decision about further action or disposal.”

In a further police statement, Det Con Pablo Beckhurst, who is leading the investigation, noted that under current law any substance which has any level of THC in it is an illegal substance under the Misuse of Drugs Act 1971.

He added that following with the Devon and Cornwall Police legal department “the issue is not so much what is on the packaging but rather what the substance contains, ie any THC.

“Some companies have been found to rely on the analysis from a third party from overseas – which may or may not relate to the sample being sold – and there is not way the police can realistically verify the reliability of the tester who appears to be overseas.

“Be that as it may, it is not a defence, even though sellers of these products believe it may be.

“A proportion of THC under the frequently mentioned 0.2 limit may justify an application for a licence to use the items in a commercial production sense – eg for the production of hemp fibre – but that is wholly different from saying you can possess or sell it as it has THC of under 0.2 percent.”

Plymouth City Council staff also joined police during the operation.

A council spokesperson said: “We are working with the police as part of a multi-disciplinary team, after two search warrants were executed this morning. We are gathering information and evidence about the use of the premise due to concerns about illegal activity.”



‘Ignorant doctors need cannabis education’ says Professor

‘Ignorant doctors need cannabis education’ says Professor


Professor Mike Barnes wrote the report on the efficacy of cannabis for the UK All Party Parliamentary Group for Drug Reform in 2016.

Man who consulted on Alfie Dingley’s case, saddened by lack of NHS prescriptions

Getting doctors to prescribe medicinal cannabis is a problem, according to one UK medical expert.


Honorary Professor of Neurogoloy at the University of Newcastle Mike Barnes, says education is needed in the field, if the profession is to make use of the country’s ‘liberal laws’.

Professor Barnes, who addressed Tynwald members yesterday (26 Mar), told the Island’s politicians that around 80% of doctors are for the medinical use of the drug ‘in theory’.

However in practice he says, they won’t prescribe it because they simply aren’t confident enough.


“The law in the UK is really quite liberal. Any specialist doctor can prescribe [cannabis] for any condition, which is probably the most liberal in europe.

“For some it’s a morality question, they just don’t agree with cannabis being legal and just won’t prescribe it but actually, that’s quite unusual.”


He estimates that some 2 million people are using cannabis illegally for medical purposes daily in the UK, though since the Home Secretary Sajid Javid had the drug rescheduled in November last year, Professor Barnes is disappointed with what has followed.

“Sadly, despite the legalisation in the UK, there hasn’t been a single NHS prescription which has been written.

To the best of my knowledge, there’s been 10 in the private sector. Which is good in some ways but bad in others because that means only at the moment it is accessible to those that can afford private prescription.”


Professor Barnes, who was instrumental in securing a licence for the family of Alfie Dingley – a young boy who suffers from epilepsy – praised the campaigns of last year, which led to the UK legalisation in specialist cases.

“Families with epileptic children are incredibly knowledgeable about cannabis and do know a lot more than the doctors.

I think from the doctors point of view, many should embrace that and learn from that.”

“There are some sadly, that are rather antagonistic to patients coming in telling them what to prescribe and how to prescribe it.

But we’re in an ironic situation, where many members of the public know more than the doctors.”

“For the last 50 + years, we’ve had cannabis portrayed to us as bad, anti establishment, no good for anything, of no medicinal use, but now all of a sudden, doctors brought up in that tradition have been told ‘well actually, for certain conditions it is quite useful.'” 


Dr Alex Allinson, who invited Professor Barnes to present to Tynwald members, has touted the Isle of Man as the perfect place to conduct research into the individual cases, should medicinal cannabis be made available

“We’re dealing with a drug that’s been around for thousands of years” he told Manx Radio, “but we’ve known about the scientific basis of the way it acts over the last couple of decades.

“So what I’m very keen on doing, if we can on the Isle of Man, is to allow people to use cannabis for medicinal purposes, but actually do some of the observational studies which are necessary to make sure it works for them.”


While the UK government introduced a change to the law, Professor Barnes notes that there hasn’t been a new health education program for doctors.

In response to this, he set up an academy for medical cannabis which offers 12, free, 20 minute modules.

This teaches doctors and health professionals he says, ‘roughly the basics’ of cannabis medicine as well as the when and how to prescribe.

“I’d like to see more of those in different formats; day seminars, week-long seminars, more detailed courses.

But I think it’s been rather sad that it’s been up to the individuals of the private sector to establish training programs, when I think it would be nice to have seen a more formalised training program from Health Education England.”


From an Isle of Man point of view, he would like to this kind of work take place with the Department of Health and Social Care through the likes of himself to establish an accredited cannabis program for GPs on Island, which doctors can enroll on before they prescribe.

Listen to this audio

More from Isle of Man News



Seth Rogen launches weed company ‘to make it easier for people to learn to love cannabis’


Seth Rogen launches weed company ‘to make it easier for people to learn to love cannabis’


Comedy movie moguls Seth Rogen and Evan Goldberg announced Wednesday the launch of Houseplant, a recreational Canadian cannabis company in collaboration with Ontario-based grower Canopy Growth.


“Houseplant is the result of years of experience and dedication, with each element and expression thoughtfully designed to make it easier for people to learn to love cannabis as much as Houseplant does,” stated a press release from the new company.


Rogen and Goldberg, both of whom were born in Vancouver, have teamed up on popular films projects including “Superbad,” “Pineapple Express” and “The Interview.” And now cannabis.


“Houseplant is a passion we’ve brought to life through drive and dedication,” Rogen said in a press release. “Every decision we’ve made for the business reflects the years of education, first-hand experience and respect we have for cannabis.”


The first strain of cannabis the new company will introduce with Canopy Growth is Houseplant Sativa and will be available for purchase in early April through regulated retailers and online in British Columbia. The company added that Houseplant Hybrid and Houseplant Indica strains, along with softgels and pre-rolled joints, will follow throughout the year

“We are so proud to be launching in Canada, our home,” Goldberg added. “After spending five years diligently preparing for the launch of this company, we’re excited to be able to share our passion for cannabis with Canadians in this way.”


While Houseplant said that its excited to make cannabis education “the center of its mission,” Canadian partner and cannabis giant Canopy Growth adds yet another celebrity duo to its growing list of business partnerships.


Last month, Canopy said that it’s working with lifestyle authority and television personality Martha Stewart to develop hemp-derived CBD products. Meanwhile, its partnership with Stewart stemmed from an earlier relationship with fellow entertainer and cannabis icon Snoop Dogg.


Canopy’s subsidiary Tweed began selling three varieties of cannabis in 2016 under the “Leafs by Snoop” brand, including varieties dubbed “Sunset,” “Ocean View” and “Palm Tree” in a nod to the rapper’s California heritage.




Can medicinal cannabis treat the tics in Tourette syndrome?


Can medicinal cannabis treat the tics in Tourette syndrome? – The University of Sydney

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

The trial is the first of its kind in Australia and will take place at Wesley Medical Research in Brisbane led by Chief Investigator and neuropsychiatrist Dr Philip Mosley. Participants will complete two periods of treatment with either a medicinal cannabis drug or a placebo, with both investigators and participants unaware of treatment status until the end of the trial.

“There is already early evidence to support the successful treatment of Tourette syndrome with cannabinoids,” said Professor Iain McGregor, Academic Director of the Lambert Initiative. “This clinical trial could have a major impact and greatly improve the lives of those living with Tourette syndrome.”

“Given the public interest in therapeutic use of cannabis, it’s important to conduct rigorous and methodologically-sound research,” Dr Mosley said. “The purpose of this clinical trial is to investigate whether medicinal cannabis is a potential therapy for people with Tourette syndrome.”


About Tourette syndrome

Tourette syndrome is a neurological disorder that develops in childhood and is characterised by involuntary movements and vocalisations (known as tics), which may be painful, embarrassing and functionally impairing.

There is currently no known cure for Tourette syndrome. Treatment aims to help control tics that inhibit everyday functioning, however current medication has been known to produce negative side effects such as weight gain, sleepiness and depression.


Tourette syndrome trial participant Chris Wright (left) and Dr Philip Mosley of Wesley Medical Research in Brisbane.

Living with Tourette syndrome

Chris Wright is the first participant in the trial. Chris developed Tourette syndrome in childhood and despite medication, his condition has persisted. Some people with Tourette syndrome experience side-effects to existing therapies including fatigue and weight gain.

At 31, Chris is working full-time in a customer service position in Brisbane and spends his day trying to regulate his tics. “Any reprieve would be very welcome. It is getting to the point where I don’t know what to do, it feels as though it all gets too much sometimes,” said Chris.

Participants in the clinical trial at Wesley Medical Research will complete two six-week “crossover” periods of treatment with active drug or placebo, with both participants and investigators unaware of treatment status until the trial is complete.

“Tourette syndrome has really been a blow to my confidence … my life in general, I often spend my days off sleeping and recovering just to do it all again,” Chris said.


The trial drugs

Medicinal cannabis, developed to pharmaceutical standards, contains a mixture of cannabidiol (CBD) and tetrahydrocannabinol (THC) – two active ingredients derived from the cannabis plant.

In collaboration with the Lambert Initiative, Bod Australia Limited will be supplying the pharmaceutical grade cannabis extract to be used in the trial. The trial will examine the safety and efficacy of cannabinoids on tic frequency as well as the psychiatric and cognitive symptoms associated with Tourette syndrome.

“Our focus is to give people like Chris these opportunities to improve their quality of life. We offer hope and answers through medical research. We are fortunate to have dedicated frontline clinicians like Dr Mosley leading this important work and donors who continue to support this valuable work,” said Dr Jennifer Schafer, Senior Clinical Trials Manager.


NHS risks thalidomide scandal repeat if doctors rush to prescribe cannabis before it is proved safe, MPs are told

NHS risks thalidomide scandal repeat if doctors rush to prescribe cannabis before it is proved safe, MPs are told


The chief scientific adviser at the Department of Health said medicinal cannabis should pass clinical trials before being made widely available


THE NHS risks a repeat of the thalidomide scandal if doctors rush to prescribe cannabis before it is proved safe, MPs were told.


Prof Chris Whitty, chief scientific adviser at the Department of Health, said it should pass clinical trials before being made widely available.


Medicinal cannabis was reclassified by the Government last year, allowing docs to prescribe it.


But campaigners have complained they are being denied NHS prescriptions because guidance on when it should be used is too restrictive.


Prof Whitty yesterday told the Commons Health Committee the drug should have the same approval process as other drugs.


He added: “History is littered with people rushing things and regretting it or, in a few cases — thalidomide probably the most well-known — having an absolute disaster.”


Thalidomide was used in the 1950s and 1960s to tackle morning sickness but led to children being born with malformed limbs.


The cannabis law was changed in November after a campaign by supporters of Alfie Dingley, seven, who had been forced to travel to the Netherlands to receive cannabis oil to treat his severe epilepsy.


Commercial Cannabis Craft Act takes aim at homegrown marijuana

Commercial Cannabis Craft Act takes aim at homegrown marijuana 

Homegrown marijuana was once a derided substance. It only got you a little bit high, and it tasted awful. Marijuana from anywhere else — Mexico, Jamaica, Colombia, Hawaii, Thailand — was preferred to a domestic product.


It’s a good thing those growers kept at it in their basements and attics, despite the derision of their friends. They figured out enough about plant genetics to flip the switch and make the domestic product the preferred bud. Some of those growers became caregivers, which became the backbone of the medical marijuana production and distribution system when the state chose not to do anything.


Now they are in the crosshairs of a legal marijuana system that wants to cut them out of the picture. Last week an unnamed Michigan group that includes Banks & Company, the Michigan Economic Stimulus Fund, and Minorities for Medical Marijuana announced the Commercial Cannabis Craft Act, which according to a press release is “a simple solution to fix licensing access and other complex Medical Marijuana issues.”


The process of getting legislators on board to introduce this legislation and then getting enough of them to change some of the existing laws is both complex and daunting. What’s questionable is why they’re introducing this now, just as Gov. Gretchen Whitmer is revamping the medical marijuana licensing and oversight system, and setting up a complementary adult-use system. Part of the governor’s process involves gathering public input. The Craft Act folks could certainly lend their efforts to that process.


I called the wrong people about this last week, so I can’t tell you what they’re thinking. I have seen the work-in-progress language of the act, and it calls for eliminating the caregiver system and banning gifting — so you can’t even give it away. It’s all couched in the language of fixing the current system, but it is very favorable to businesses that are already operating.


A lot of the same points made in the Craft Act press release are also made pretty boldly in a policy statement a New York marijuana industry group sent to Gov. Andrew Cuomo as he formulates a recreational marijuana system. That policy statement is a vicious attack on home grow provisions, claiming that “home grow will make it impossible to eliminate the black market.”

The gang that wants to move the black market to the stock market considers that a big issue. The Craft Act folks address this in their press release by claiming that, because of caregivers, “there’s potential for illegal marijuana to get into the [black] market.”


This is really ironic. All marijuana was illegal for a long time, and now folks are working at differentiating between legal marijuana and illegal marijuana. It’s suggestive of an old argument against hemp legalization — because police wouldn’t be able to tell the difference between hemp plants and marijuana plants. The recent New York policy statement echoes that in claiming that “home grow will make it impossible for law enforcement to distinguish between legal and illegal products” — again casting doubt on the deductive skills of police officers.


So we still have to quibble about where the illegal marijuana is so law enforcement still has some reason to chase marijuana sellers around. This is the time to protect the interests of those who are legally licensed to sell marijuana. This may get even weirder before it all shakes out.

Another aspect to this legal vs. illegal marijuana is the assurance that the licensed outlet is selling safe, clean, tested, and state-compliant marijuana. The Craft Act group, and pretty much everyone else selling marijuana products, want to assure people that their marijuana products are safe and all that — not like that nasty black market stuff that could be laced with all sorts of things. This is a good thing, particularly when it comes to medical product. However, at this point the recreational users just don’t care. They’ve been using untested marijuana since forever. Ever since the paraquat herbicide scare, and every other scare over the years, marijuana users have continued to use the stuff.


That’s not to mean that growers who use unscrupulous methods and sell poisonous crap don’t need to be eliminated. They do. But a lot of medical and recreational users know and trust their growers. They know and trust the products they’ve been getting. Not only that, the stores have not been able to maintain a sure supply of anything so far. It’s going to take a long time for the legalized market to capture the trust of marijuana users. Medical users have had the issue of provisioning centers not being a source where what you need is always available. Gaining integrity in this area will take some doing.


It won’t help the legal market if the public perception is that money-grabbing big businesses are trying to lock up the market for themselves at the expense of the small-timers. The market will get bigger when the recreational market opens. Folks who have sunk their money and hopes and dreams of getting rich want to see some return. They see an opportunity for a big influx of cash if the recreational market were opened to them as quickly as possible. They are tempted by the people who ask if they can buy recreational marijuana at their stores.


In the long run, the caregiver system cannot compete with a robust legal market. The number of licensed caregivers in the state is governed by the amount of patients. Right now there are fewer than 300,000 patients in the state, and not all of them have caregivers. The Michigan market for recreational marijuana is somewhere around 2 million if national averages apply here. The amount of caregivers for, who knows, 100,000 patients, can’t do that much in a market for 2 million even if they do “accidentally” grow a little too much.

The people who grow for their own use are like the folks who brew their own beer or make their own wine. They may do a little “gifting” here and there, but they still go out and have a few at the bar or with dinner. And they certainly aren’t competing with the marketplace.


It’s clear that the medical marijuana system and the recently passed Prop. 1 legalizing adult recreational use of marijuana have not had a chance to thrive as written. The marijuana activist community now has the ears of the governor and the attorney general. That was clear from AG Dana Nessel last week when she said she credits the marijuana crowd for putting her in office.


This Craft Act maneuver seems an end run designed to bypass the governor’s initiative and lock out some players to the advantage of others. This won’t be the last we see of that kind of action. It’s also not the end of homegrown marijuana — a category of herb that still maintains its place at the center of dispute.

IE: Man took cannabis to gardaí to complain about the quality




A CANNABIS user took a bag of the drug to a garda station to complain that it was “not of good quality”.

Arthur Liwembe (33) was immediately arrested after he went to the station of his own accord and presented the cannabis to a garda on duty to say he was not happy with his purchase.

Judge John Hughes said Liwembe’s behaviour was “illogical to say the least” and was indicative of a cannabis-induced “psychosis”.

He adjourned the case for a probation report.

Liwembe, a former student nurse with an address at an asylum-seekers’ reception centre, pleaded guilty to unlawful possession of cannabis and other charges.

Gda Ian Foley told Dublin District Court Liwembe went to Kilmainham Garda Station last July 10 and produced a bag of cannabis valued at €10 from his pocket.

He was searched and a box-cutter knife was found on him. The blade was for use in his work as a handyman, said defence solicitor Anne Fitzgibbon.

Gda Foley told Judge Hughes that he believed Liwembe was suffering from problems at the time.

“He said he had bought the drugs and believed them not to be of good quality and that was why he attended the garda station,” Gda Foley said.

He was arrested on a later date when he returned, asked for the confiscated knife to be returned and became aggressive when this was refused.

Separately, Liwembe admitted repeatedly trespassing at an address where he used to live and work at Tyrconnell Road, Inchicore.

The court heard he got in without permission and damaged an internal door on one occasion.

Once, he was discovered in a bedroom and told gardai he was “just trying to sleep” and was under the “misapprehension that he still lived there”.

The accused came here from Malawi in 2012 as a student nurse but his visa ran out and he applied for residency on the basis of having an Irish-born child, Ms Fitzgibbon said.

Liwembe had been using cannabis, which could lead to “transient psychotic symptoms”, the lawyer added.

He was now off the drug.

Judge Hughes remanded him on continuing bail.



Link – https://www.independent.ie/irish-news/courts/man-took-cannabis-to-garda-to-complain-about-the-quality-37947406.html


CA: Don’t tax medicine

so, how’s it going in canada then.. lol 

Logo for Don't Tax MedicineFrançais
Write a letter to your local MP, provincial MPP/MLA, and members of the House Standing Committee on Finance, urging them to remove taxes on medical cannabis.


Taxing Medical Cannabis Hurts All Canadians


The Government of Canada must eliminate all taxes on medical cannabis.

Unlike other medicines, medical cannabis is taxed out of moral judgment, greed, and government overreach.

Taxing medical cannabis harms vulnerable Canadians who are in need of medical treatment, and they need our help right now.


Many medical cannabis patients are struggling with the costs of healthcare, and these unjust taxes make it harder to afford their medicine. Over-taxing leads to under-dosing, it forces desperate patients into the unregulated black market, and it adds stress on our public health system — a cost that is passed on to all taxpayers.


It’s likely that taxes on medical cannabis are hurting you or someone you love. Seniors, veterans, and sick children are among the hundreds of thousands of ordinary Canadians who rely on medical cannabis every day. 


By placing unjust taxes on medicine, our Government is hurting people they should be helping.


The 2019 Federal Budget is due to be announced by the Finance Minister at the end of February. Parliament has the opportunity to remove these taxes before the 2019 Budget is finalized.Call on your elected representatives right now, and tell them to remove all taxes on medical cannabis before the budget announcement.


Stand with patients and tell our government: Don’t Tax Medicine!


Write a letter to your local MP, provincial MPP/MLA, and members of the House Standing Committee on Finance, urging them to remove all taxes on medical cannabis.


First U.S. Clinical Trial Looking at Cannabinoids and Traumatic Brain Injury A groundbreaking study expected to begin soon


Sign up email info to be part of study is at the bottom of article.
See also … 

Two prominent Colorado institutions just announced a collaboration on the first clinical trial in the U.S. to analyze the effects of plant-derived cannabinoids on trauma to the brain.

The Flowering HOPE Foundation from Boulder and the Clover Leaf University from Denver have partnered to research how cannabinoids can impact recovery from traumatic brain injury. This is the first clinical trial of its kind to be conducted in the United States. It will assess quantitative EEG brain activity and a cannabinoid-reactive salivary biomarker in 40 patients suffering from mild traumatic brain injury against a control group taking hemp-derived cannabinoid supplements. Researchers are currently recruiting 18 to 55 year old subjects to participate in the trial, which is expected to last one year.

Cannabinoids brain injury research

According to Jason Cranford, Founder of the Flowering HOPE Foundation, “We hope to provide scientific support for the benefits of the natural plant-based compounds contained in hemp and move a step closer towards the unrestricted availability of non synthetic cannabinoid therapeutics.” The Flowering HOPE Foundation is a non-profit organization that supports and studies the medicinal use of plant-derived cannabinoids. Cranford himself has over 25 years of experience in cultivation, extractions, and research.

cannabinoids brain injury Researchers are looking at the link between cannabinoids and recovery from traumatic brain injury

Their partner on this project, Clover Leaf University, is the first accredited university to specialize in phytotechnology. Chloe Villano, President and Founder, is renowned for her years of work in the cannabis and hemp industries. She mentioned her motivations for participating in the cannabinoids brain injury study:

“This historic study is the first of its kind and it is a privilege to work with the Flowering HOPE Foundation to address the problem of brain injury and collaborate with a neuroscientist who understands the brain endocannabinoid system, such as Dr. Cooper. There are currently no effective treatments for traumatic brain injury or chronic traumatic encephalopathy, but phytocannabinoids may be a good candidate, based on the established science of anti-inflammatory and neuroprotective mechanisms. Clover Leaf University is excited to take the lead in clinical studies that will improve and save lives,” said Villano.

Doctor Don Cooper Ph.D. (mentioned above) has been studying cannabinoids for nearly two decades and has published 45 peer reviewed papers on neuronal memory formation and plasticity. “I never thought it would take almost 20 years from when I started working on the brain cannabinoid system to have the first approved clinical study on phytocannabinoids and brain injury. We have convincing preclinical data showing that phytocannabinoids are neuroprotective and may be critically important for restoring neuronal function after brain injury,” stated Cooper.

For more information or to participate in this study, contact the Clinical Coordinator at TBIstudy@protonmail.com

Your message has been successfully sent.
Oops! Something went wrong.

Get in touch

If you wish to enquire about anything, or just say hi, please fill in the form opposite, or email us on:

Copyright 2020 Smoke.me.uk